Spero Therapeutics (NASDAQ:SPRO) reported quarterly earnings of $0.53 per share which beat the analyst consensus estimate of $(0.40) by 232.5 percent. This is a 239.47 percent increase over losses of $(0.38) per share from the same period last year. The company reported $41.297 million in sales this quarter. This is a 174.51 percent increase over sales of $15.044 million the same period last year.